To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
Karmanos Cancer Institute is the only hospital in Michigan focused solely on cancer. That means we're completely devoted to offering every patient the best treatment options. From groundbreaking original research to offering the most up-to-date treatment options, Karmanos' experts offer tomorrow's standard of care today.
We believe that patients, referring physicians, and the Karmanos Cancer Institute staff are all critical members of the treatment team. We are committed to proactive, candid, timely communication so everyone knows where their case stands and is prepared to participate in meaningful ways. Superior communication means everyone can do their job better. Learn more about how we guide our patients through the health care system with Cancer Care Navigators.
HealthLeaders Oncologists expect patients to get a second opinion when they are diagnosed with cancer; it's best practice. According to George Yoo...
The Barbara Ann Karmanos Cancer Institute is partnering with Wayne State University (WSU) School of Medicine and RepEaters CrossFit in Commerce To...
Patient Power Research presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting examined Bruton tyrosine kinase BTK inhib...